- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03282630
The Effects of Sphenopalatine Ganglion Acupuncture in Patients With Seasonal Allergic Rhinitis
The Effects of Sphenopalatine Ganglion Acupuncture in Patients With Seasonal Allergic Rhinitis: A Randomized Trial
Sphenopalatine ganglion (SPG)-acupuncture has been shown to exhibit distinct effects in treatment of nasal inflammatory disease. Investigators aimed to assess the effects of SPG acupuncture in patients with seasonal allergic rhinitis. The randomized, double-blind, controlled clinical trial enrolled participants with seasonal allergic rhinitis. Participants will be randomly assigned to either active SPG-acupuncture group or sham-acupuncture group. All participants will be provided four times of acupuncture in 4 weeks, and then follow-up of 4 week.
Primary trial outcomes are change in symptoms and change in need for medication. The primary outcomes will be measured in baseline, week1, week2, week3, week4, week 6 and week 8. Secondary outcomes include the changes in nasal patency (nasal airway resistance and nasal cavity volume), exhaled nasal nitric oxide.The investigators also evaluate change in neuropeptides (substance P, vasoactive intestinal peptide,neuropeptide Y) and inflammatory cytokines (interleukin(IL)-4, IL-5, IL-8, IL-17a, IL-22, IL-25, interferon-γ, tumor necrosis factor-α, transforming growth factor(TGF)-β1, TGF-β2, TGF-β3,Chemokine, Eotaxin) in nasal secretions as secondary outcomes. The secondary outcomes will be measured in baseline, week1, week4 and week 8.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Beijing Tongren Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with a history of at least 2 years of seasonal allergic rhinitis
- no smoking
- without history of nasal polyps, nasal septum deviation and history of nose surgery) or lung disease (asthma, chronic obstructive pulmonary disease and fibrosis)
- free of upper and lower respiratory tract infections for at least 4 weeks before beginning the study.
Exclusion Criteria:
- had received acupuncture within the last four weeks before the study
- history of diabetes mellitus, autonomic neuropathy, coronary heart disease or hypertension.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: active acupuncture
Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side).
The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process.
The needle was rotated until the participant felt "de-qi" sensations.
|
|
|
Sham Comparator: sham acupuncture
Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion.
But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of symptoms
Time Frame: The primary outcomes will be measured in baseline, week1, week2, week3, week4, week 6 and week 8.
|
The participants will document the four nasal symptoms (nasal obstruction, rhinorrhea, sneezing, and itching) involved in assigning the total nasal symptom score(TNSS).
The symptoms are graded on a four-point scale (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms).
The weekly TNSS will be calculated and compared between the groups.
|
The primary outcomes will be measured in baseline, week1, week2, week3, week4, week 6 and week 8.
|
|
The change of need for medication
Time Frame: The primary outcomes will be measured in baseline, week1, week2, week3, week4, week 6 and week 8.
|
Participants will be asked not to use drugs as much as possible.
If drugs are used to relieve symptoms, Medication need will be measured using rescue medication score (RMS), comprising the weekly sum of daily assessments.
|
The primary outcomes will be measured in baseline, week1, week2, week3, week4, week 6 and week 8.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of nasal patency
Time Frame: The outcomes will be measured in baseline, week1, week4 and week 8.
|
Acoustic rhinometry was performed to measure the total nasal cavity volume (cm³) and Rhinomanometer was used to measure the total nasal airway resistance (Pa·cm-³·s-1) .
|
The outcomes will be measured in baseline, week1, week4 and week 8.
|
|
The change of exhaled nasal nitric oxide
Time Frame: The outcomes will be measured in baseline, week1, week4 and week 8.
|
The change of exhaled nasal nitric oxide assessed by nitric oxide analyser.
A nitric oxide analyser was used to measure exhaled nasal nitric oxide (nNO).
Briefly, NO-free air was aspirated through the nasal cavity at a flow rate of 50 ml/s.
The subject exhaled against the air-resistance, resulting in an intraoral pressure to close the velum and prevent mixture of oral and nasal gas.
Nasal gas from this circuit was continuously routed in part directly into the analyser for determination of nNO, and the level of nNO(ppb) was calculated from a plateau lasting for at least 3s.
|
The outcomes will be measured in baseline, week1, week4 and week 8.
|
|
The change of substance P, vasoactive intestinal peptide and neuropeptide Y in nasal secretions
Time Frame: The outcomes will be measured in baseline, week1, week4 and week 8.
|
The change of substance P, vasoactive intestinal peptide and neuropeptide Y in nasal secretions were analysed by Enzyme linked immunosorbent assay.
Nasal secretions were obtained by inserting a postoperative sinus pack in the nasal cavity (acupuncture side) for five minutes.
The quantity of secretions was determined by comparing the weight of the sponges before and after insertion and 2 ml of 0.9% sodium chloride solution was added to each sponge.
The sponges were stored at 4°C for two hours and the nasal secretions were recovered from the sponges by centrifugation at 1500 g for 15 minutes at 4°C.
The supernatants were separated and stored in aliquots at -20°C until further analysis.
The levels of substance P(pg/ml), vasoactive intestinal peptide (ng/ml) and neuropeptide Y (pg/ml) were analysed.
|
The outcomes will be measured in baseline, week1, week4 and week 8.
|
|
The change of inflammatory cytokines in nasal secretions
Time Frame: The outcomes will be measured in baseline, week1, week4 and week 8.
|
The change of inflammatory cytokines (interleukin(IL)-4, IL-5, IL-8, IL-17a, IL-22, IL-25, interferon-γ, tumor necrosis factor-α, transforming growth factor(TGF)-β1, TGF-β2, TGF-β3,Chemokine, Eotaxin) in nasal secretions as secondary outcomes.
Nasal secretions were obtained by inserting a postoperative sinus pack in the nasal cavity (acupuncture side) for five minutes.
The quantity of secretions was determined by comparing the weight of the sponges before and after insertion and 2 ml of 0.9% sodium chloride solution was added to each sponge.
The sponges were stored at 4°C for two hours and the nasal secretions were recovered from the sponges by centrifugation at 1500 g for 15 minutes at 4°C.
The supernatants were separated and stored in aliquots at -20°C until further analysis.
The levels of inflammatory cytokines (pg/ml) were analysed using the Luminex System.
|
The outcomes will be measured in baseline, week1, week4 and week 8.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chengshuo Wang, Beijing Tongren Hospital
Publications and helpful links
General Publications
- Choi SM, Park JE, Li SS, Jung H, Zi M, Kim TH, Jung S, Kim A, Shin M, Sul JU, Hong Z, Jiping Z, Lee S, Liyun H, Kang K, Baoyan L. A multicenter, randomized, controlled trial testing the effects of acupuncture on allergic rhinitis. Allergy. 2013 Mar;68(3):365-74. doi: 10.1111/all.12053. Epub 2012 Dec 18.
- Xue CC, Zhang AL, Zhang CS, DaCosta C, Story DF, Thien FC. Acupuncture for seasonal allergic rhinitis: a randomized controlled trial. Ann Allergy Asthma Immunol. 2015 Oct;115(4):317-324.e1. doi: 10.1016/j.anai.2015.05.017. Epub 2015 Jun 11.
- Brinkhaus B, Ortiz M, Witt CM, Roll S, Linde K, Pfab F, Niggemann B, Hummelsberger J, Treszl A, Ring J, Zuberbier T, Wegscheider K, Willich SN. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med. 2013 Feb 19;158(4):225-34. doi: 10.7326/0003-4819-158-4-201302190-00002.
- Wang K, Chen L, Wang Y, Wang C, Zhang L. Sphenopalatine Ganglion Acupuncture Improves Nasal Ventilation and Modulates Autonomic Nervous Activity in Healthy Volunteers: A Randomized Controlled Study. Sci Rep. 2016 Jul 18;6:29947. doi: 10.1038/srep29947.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms
- Hypersensitivity, Immediate
- Cysts
- Connective Tissue Diseases
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Mucinoses
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Ganglion Cysts
Other Study ID Numbers
- TR-acupuncture-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients
-
Beni-Suef UniversityCompletedSeptic Patients | Nonseptic PatientsEgypt
-
Universidade Federal de PernambucoCompleted
-
EarlySense Ltd.WithdrawnPost Operative Patient | Patients Requiring PCA | Respiratory Patients | Patients in Risk of FallUnited States
-
Medical University of GrazMedical University of Vienna; Luzerner Kantonsspital; Universitätsklinikum Hamburg-Eppendorf and other collaboratorsNot yet recruiting100 Stage I Patients | 100 Metastatic Patients
-
Bayside HealthCompletedMechanically Ventilated Patients | Intensive Care | Sedated PatientsAustralia
-
Fondazione IRCCS Policlinico San Matteo di PaviaRecruitingInfections | Transplant Patients | Immunocompromised PatientsItaly
-
Hopital of MelunCompletedCritical Ill Patients | Ventilated PatientsFrance
-
RWTH Aachen UniversityCompletedCardiac Surgery Patients | Elderly Patients | Neurosurgical Patients | Obese Patients | Abdominal Surgery PatientsGermany
-
Baylor Research InstituteEnrolling by invitationBDE for Hernia Patients | Exparel for Hernia PatientsUnited States
-
Meir Medical CenterUnknownPatients With Normal ECG | Patients With Pathological ECGIsrael
Clinical Trials on Sphenopalatine ganglion acupuncture
-
Beijing Tongren HospitalCompleted
-
Shanghai Institute of Acupuncture, Moxibustion...Not yet recruitingGeographic AtrophyChina
-
BrainsGateCompletedIschemic StrokeIsrael, Hong Kong, Denmark, Spain, France, Finland, United States, Serbia, Czechia, Italy, Portugal, Germany, Georgia, Poland, Canada, North Macedonia, Slovakia, Ukraine
-
Ankara City Hospital BilkentCompletedMigraine Disorders, Facial Pain Disorder, Cluster Headache, Trigeminal Neuralgia, Trigeminal Autonomic CephalalgiasTurkey (Türkiye)
-
Tanta UniversityCompletedUltrasound | Functional Endoscopic Sinus Surgery | Sphenopalatine Ganglion Block | Brainlab NavigationEgypt
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Federal University of São PauloCompletedIntraocular Pressure | Osteopathic Manipulative TreatmentBrazil
-
Saglik Bilimleri Universitesi Gazi Yasargil Training...CompletedPostoperative AnalgesiaTurkey (Türkiye)
-
New York State Psychiatric InstituteCompleted
-
Ajou University School of MedicineCompletedSphenopalatine Ganglion BlockKorea, Republic of